MedTrace Logo

Role of Dexamethasone in Transversus Abdominis Plane Block After Cesarean Section

NCT03767920 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2020-08-05

No results posted yet for this study

Summary

Our aim to study the efficacy of bupivacaine 0.25% with dexamethasone and that of bupivacaine 0.25% alone in transversus abdominis plane (TAP) block for postoperative analgesia in patients undergoing an elective Caesarean section.

* Group 1: bupivacaine 0.25% + dexamethasone 8 mg
* Group 2: bupivacaine 0.25% A prospective Randomized Interventional double-blind study.

Conditions

  • Cesarean Section

Interventions

DRUG

bupivacaine

TAP block with 20 ml of 0.25% bupivacaine bilaterally

DRUG

dexamethasone

TAP block with 4 mg dexamethasone bilaterally

DRUG

placebo to dexamethasone

TAP block with 4 mg placebo to dexamethasone bilaterally

Sponsors & Collaborators

  • Aswan University Hospital

    lead OTHER

Principal Investigators

  • hany f sallam, md · Aswan University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2020-03-30
Completion
2020-08-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03767920 on ClinicalTrials.gov